BioLinker raises $1.68M to synthesise DNA and train AI in the Amazon
What's the deal? Brazilian biotech BioLinkerDealroom has a profile for this one. Try Dealroom → has raised US$2.15M (roughly $1.68 million) in an early-stage round led by Axcell, an Amazon-focused accelerator, with participation from research foundation FAPESP. Axcell contributed US$1.84M; the rest came from FAPESP's PIPE Phase 2 program.
What does it do? Founded in 2018 by scientists from the University of São Paulo, BioLinker uses synthetic biology to discover, develop, and manufacture recombinant proteins. It already generates recurring revenue and funds its commercial development from operations.
What's the money for? The capital will fund an automated laboratory at the Amazon Biobusiness Center in Manaus, where BioLinker plans to install robots to run high-throughput screening. The method generates data at scale to train artificial intelligence models and expand domestic DNA production.
Why Manaus? Companies in the Manaus Free Trade Zone must invest in innovation, and Axcell's fund pools those resources through a regional bioeconomy program that issues cheques of up to US$2.56M to biotech firms. In exchange, BioLinker committed to growth targets in the Amazon region and opened a branch there.
The work's biggest cost is data. "Obtaining data at the speed we need to train models would require much more capital, and the round was consolidated with exactly that in mind," founder and chief executive officer Mona Oliveira told StartupsDealroom has a profile for this one. Try Dealroom → (translated from Portuguese).
What's the endgame? BioLinker wants national autonomy in producing large DNA blocks, which Oliveira says no Brazilian company currently makes. "Today, in Brazil, no one produces this," she said, adding that the country depends entirely on importing the material.
The company sold 13% of its equity in this part of the round, which is not yet fully closed. Oliveira wants at least one international investor to join — even with a small cheque — to accelerate its AI design-build-test cycle and help structure a Series A abroad within two years.
What could go wrong? BioLinker plans to work mainly with Brazilian genetic heritage, including bacterial and phage genomes. Oliveira noted a regulatory push to prevent AI-designed viruses, so the company's proposal includes protecting the genetic data it handles.
The signal: The round sits in the smaller tier of disclosed deals by amount, reflecting the early stage of Brazil's domestic biotech infrastructure. By anchoring a DNA-synthesis and AI lab in the Amazon, BioLinker is betting that local biodiversity and the Free Trade Zone's innovation mandate can seed a supply chain the country currently lacks.
Read more: startups.com.br
Image credit: NIH-NCATS
